Sienna Gestion Boosts Stock Holdings in AbbVie Inc. $ABBV

Sienna Gestion increased its holdings in AbbVie Inc. (NYSE:ABBV) by 712.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,255 shares of the company’s stock after buying an additional 35,298 shares during the period. Sienna Gestion’s holdings in AbbVie were worth $8,498,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. grew its stake in AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after purchasing an additional 789 shares during the last quarter. Penserra Capital Management LLC raised its holdings in AbbVie by 500.0% in the second quarter. Penserra Capital Management LLC now owns 864 shares of the company’s stock worth $159,000 after purchasing an additional 720 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new position in AbbVie in the second quarter worth about $581,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research firms have recently weighed in on ABBV. Morgan Stanley raised their price target on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Barclays began coverage on shares of AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. Citigroup lowered their target price on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Stock Down 0.8%

AbbVie stock opened at $230.41 on Monday. The stock has a 50-day moving average price of $224.72 and a 200 day moving average price of $224.21. The company has a market capitalization of $407.40 billion, a price-to-earnings ratio of 97.63, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the company earned $2.16 EPS. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s payout ratio is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.